BSFA 주식 개요 는 미국과 캐나다에서 브랜드 및 일반 처방 의약품을 개발, 제조 및 판매하는 바이오 제약 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
ANI Pharmaceuticals, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 ANI Pharmaceuticals 과거 주가 현재 주가 US$55.50 52주 최고치 US$64.00 52주 최저치 US$47.80 베타 0.74 1개월 변경 4.72% 3개월 변경 사항 4.72% 1년 변경 사항 8.82% 3년 변화 70.25% 5년 변화 -5.13% IPO 이후 변화 1,069.16%
최근 뉴스 및 업데이트
ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025 Jan 13
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity Jan 02
Senior VP of Finance & CFO recently sold €399k worth of stock Dec 19
President recently sold €194k worth of stock Nov 29
Senior Vp & Head of Rare Disease recently sold €356k worth of stock Nov 19
Third quarter 2024 earnings released: US$1.27 loss per share (vs US$0.46 profit in 3Q 2023) Nov 09 더 많은 업데이트 보기
ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025 Jan 13
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity Jan 02
Senior VP of Finance & CFO recently sold €399k worth of stock Dec 19
President recently sold €194k worth of stock Nov 29
Senior Vp & Head of Rare Disease recently sold €356k worth of stock Nov 19
Third quarter 2024 earnings released: US$1.27 loss per share (vs US$0.46 profit in 3Q 2023) Nov 09
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024 Nov 08
ANI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 31
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Estradiol Gel, 0.06% Oct 25
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others. Sep 17 Alimera Sciences, Inc. Takes Legal Action Against ANI Pharmaceuticals, Inc. to Enforce Merger Agreement Sep 11
Second quarter 2024 earnings released: US$0.14 loss per share (vs US$0.30 profit in 2Q 2023) Aug 07
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2024 Aug 06
ANI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of L-Glutamine Oral Powder Jul 15
ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell 3000E Value Index Jul 03
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP Jul 02 ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million. Jun 25
Senior VP of Finance & CFO recently sold €292k worth of stock Jun 09
President recently sold €1.0m worth of stock May 17
ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 May 11
First quarter 2024 earnings released: EPS: US$0.93 (vs US$0.056 in 1Q 2023) May 10
ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024 Apr 20
ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension Apr 10
ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024 Apr 06
ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP Mar 27
Independent Director recently sold €420k worth of stock Mar 08
Full year 2023 earnings released: EPS: US$0.95 (vs US$3.05 loss in FY 2022) Mar 01
ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 Feb 29
ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024 Feb 08
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP Jan 24
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP Jan 16
Head of Rare Disease recently sold €148k worth of stock Nov 14
New minor risk - Share price stability Nov 10
Third quarter 2023 earnings released: EPS: US$0.51 (vs US$0.55 loss in 3Q 2022) Nov 09
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023 Nov 09
ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 26
Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares Oct 05
Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1% Aug 29
ANI Pharmaceuticals, Inc. Announces Board Changes Aug 24
President recently sold €3.0m worth of stock Aug 17
Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.94 loss in 2Q 2022) Aug 10
Forecast breakeven date moved forward to 2023 Aug 10
ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023 Aug 10
ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 01
New minor risk - Profitability Jul 24 ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million. May 13
First quarter 2023 earnings released: EPS: US$0.063 (vs US$1.27 loss in 1Q 2022) May 09 ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023
Full year 2022 earnings released: US$3.05 loss per share (vs US$3.40 loss in FY 2021) Mar 10
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP Dec 20
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP Nov 29
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP Nov 17
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.37 loss in 3Q 2021) Nov 10
Ani Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2022 Nov 10
ANI Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 25
ANI Pharmaceuticals, Inc. Appoints Krista Davis as Chief Human Resources Officer Sep 13
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP Aug 30
Key Executive recently sold €661k worth of stock Aug 18
ANI Pharmaceuticals, Inc. Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP Aug 17 ANI Pharmaceuticals, Inc. Reports Impairment Charge for the Second Quarter Ended June 30, 2022
Second quarter 2022 earnings released: US$0.94 loss per share (vs US$1.17 loss in 2Q 2021) Aug 08
Ani Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP Aug 04
ANI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary Jul 19
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP Jun 02
ANI Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022 May 12
First quarter 2022 earnings released: US$1.27 loss per share (vs US$0.007 profit in 1Q 2021) May 10
High number of new directors Apr 27
ANI Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022 Apr 20
ANI Pharmaceuticals, Inc. Announces the Launch of Misoprostol Tablets Apr 12
Chairman recently bought €126k worth of stock Mar 23
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 16
ANI Pharmaceuticals Announces Executive Changes Feb 25
ANI Pharmaceuticals, Inc., Annual General Meeting, Apr 27, 2022 Feb 16
Oakrum Pharma and ANI Pharmaceuticals Announce the Launch of Betaine Anhydrous Powder, the first Generic Version of Cystadane® Powder, Including 180 Days of Exclusivity Feb 15
ANI Pharmaceuticals Announces Commercial Availability of Purified Cortrophin™ Gel for Multiple Chronic Autoimmune Disorders Jan 25
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Rifabutin Capsules USP Dec 22
Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc Announce Commercial Availability of Carglumic Acid Tablets Dec 21
Independent Director recently bought €87k worth of stock Dec 08
ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Novitium Pharma LLC. Nov 24
ANI Pharmaceuticals, Inc. announced that it has received $25 million in funding from Ampersand Management LLC Nov 23
Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.035 profit in 3Q 2020) Nov 04
ANI Pharmaceuticals, Inc. Announces Launch of Nebivolol Tablets Sep 20
Ani Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome Sep 02
Second quarter 2021 earnings released: US$1.17 loss per share (vs US$1.03 loss in 2Q 2020) Aug 08 ANI Pharmaceuticals, Inc.(NasdaqGM:ANIP) dropped from Russell Microcap Growth Index
First quarter 2021 earnings released: EPS US$0.007 (vs US$0.59 loss in 1Q 2020) May 08 주주 수익률 BSFA DE Pharmaceuticals DE 마켓 7D 1.8% 1.5% 1.9% 1Y 8.8% -7.6% 15.1%
전체 주주 수익률 보기
수익률 대 산업: BSFA 지난 1년 동안 -7.6 %를 반환한 German Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: BSFA 지난 1년 동안 15.1 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is BSFA's price volatile compared to industry and market? BSFA volatility BSFA Average Weekly Movement 4.6% Pharmaceuticals Industry Average Movement 5.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: BSFA 지난 3개월 동안 German 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: BSFA 의 주간 변동성 ( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 바이오 제약 회사인 ANI Pharmaceuticals는 미국과 캐나다에서 브랜드 및 일반 처방 의약품을 개발, 제조, 판매하는 회사입니다. 이 회사는 경구용 고형제, 반고형제, 액상제, 국소제, 규제 약물, 강력한 제품을 제조할 뿐만 아니라 의약품 위탁 개발 및 제조를 수행합니다. 이 회사는 소매 약국 체인, 도매업체, 유통업체 및 우편 주문 약국, 단체 구매 조직, 전문 약국 및 병원을 통해 제품을 판매합니다.
자세히 보기 ANI Pharmaceuticals, Inc. 기본 사항 요약 ANI Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요? BSFA 기본 통계 시가총액 €1.10b 수익(TTM ) -€8.46m 수익(TTM ) €535.85m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) BSFA 손익 계산서(TTM ) 수익 US$555.46m 수익 비용 US$223.35m 총 이익 US$332.11m 기타 비용 US$340.87m 수익 -US$8.77m
주당 순이익(EPS) -0.45 총 마진 59.79% 순이익 마진 -1.58% 부채/자본 비율 145.2%
BSFA 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/01 03:54 장 마감 주가 2025/01/31 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 ANI Pharmaceuticals, Inc. 13 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Dewey Steadman Canaccord Genuity Louise Chen Cantor Fitzgerald & Co. Timothy Chiang Capital One Securities, Inc.
10 더 많은 분석가 보기 
